RE-BVS – Piemonte Repository

Sfoglia per AUTORE
TORRI V
Collezione AOU San Luigi di Orbassano

Items : 10

International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2022 Jan;33(1):57-66. doi: 10.1016/j.annonc.2021.09.017. Epub 2021 Oct 5.

2022
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
AOU San Luigi di Orbassano

Scagliotti GV; Caffo O; Irtelli L; Wiest G; Monica V; Porcu L; Manegold C; Dickgreber NJ; Bearz A; Pedrazzoli P; Follador A; Folprecht G; Griesinger F; Schmid-Bindert G; Reck M; Morabito A; Santo A; Gregorc V; Chiari R; Schena M; Borra G; Valmadre G; Ceribelli A; Kropf-Sanchen C; Stoelben E; Geissler M; Colantonio I; Cauchi C; Ladage D; et alii...

Corrigendum to "International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer": [Annals of Oncology 33 (2022) 57-66]. in Annals of oncology : official journal of the European Society for Medical Oncology / Ann Oncol. 2022 Apr;33(4):454. doi: 10.1016/j.annonc.2022.01.005. Epub 2022 Jan 25.

2022
AO Cuneo
AOU Città della Salute di Torino
AOU Novara
AOU San Luigi di Orbassano

Manegold C; Scagliotti GV; Torri V; Grohe C; Porcu L; Follador A; Monica V; Wiest G; Irtelli L; Dickgreber NJ; Bearz A; Caffo O; Pedrazzoli P; Chiari R; Reck M; Schmid-Bindert G; Folprecht G; Griesinger F; Gregorc V; Santo A; Stoelben E; Ceribelli A; Serke M; Morabito A; Schena M; Valmadre G; Borra G; Kropf-Sanchen C; Colantonio I; et alii...

PS01.04 International Tailored Chemotherapy Adjuvant Trial : ITACA Trial. Final Results in Journal of Thoracic Oncology

2021
AO Cuneo
AOU Città della Salute di Torino
AOU San Luigi di Orbassano

Scagliotti G; Porcu L; Arizio F; Spatafora M; Righi L; Torri V; Wiest GH; Sotoparra H; Schumann C; Valmadre G; Borra G; Schena M; Morabito A; Santo A; Chiari R; Gregorc V; Reck M; Manegold C; Griesinger F; Follador A; Ferrari A; Bearz A; Caffo O; Irtelli L; Dickgreber N; Cecere F; Schutte W; Stoelben E; Geissler M; et alii...

The elderly patient individualized chemotherapy (EPIC) trial, a study for an aged population of non-small cell lung cancer in Annals of Oncology

2019
AOU San Luigi di Orbassano

Passiglia F; Capelletto E; Grossi F; Bidoli P; Galetta D; Follador A; Valmadre GP; Defferrari C; Caffo O; Bearz A; Colantonio I; Gregorc V; Scotti V; Cognetti F; Cordero L; Arizio F; Novello S; Torri V; Scagliotti G;

Chemotherapy versus erlotinib as second-line treatment in patients with advanced non-small cell lung cancer and wild-type epidermal growth factor receptor: an individual patient data (IPD) analysis. in ESMO open / ESMO Open. 2018 Nov 1;3(6):e000327. doi: 10.1136/esmoopen-2018-000327. eCollection 2018.

2018
AOU San Luigi di Orbassano

Garassino MC; Kawaguchi T; Gregorc V; Rulli E; Ando M; Marsoni S; Isa SI; Novello S; Farina G; Barni S; Torri V; Cinquini M;

Individual patients data analysis (IPD) of three randomized studies comparing erlotinib (E) with chemotherapy (CT) in patients with advanced wild-type epidermal growth factor receptor (wtEGFR) non-small cell lung cancer (NSCLC) in Journal of Clinical Oncology

2015
AOU San Luigi di Orbassano

Torri V; Ando M; Rulli E; Floriani IC; Kawaguchi T; Isa S-C; Gregorc V; Novello S; Barni S; Cinquini M; Marsoni S; Farina G; Garassino MC;

Does surgery improve survival of patients with malignant pleural mesothelioma?: a multicenter retrospective analysis of 1365 consecutive patients. in Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer / J Thorac Oncol. 2014 Mar;9(3):390-6. doi: 10.1097/JTO.0000000000000064.

2014
AOU San Luigi di Orbassano

Bovolato P; Casadio C; Billè A; Ardissone F; Santambrogio L; Ratto GB; Garofalo G; Bedini AV; Garassino M; Porcu L; Torri V; Pastorino U;

Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified, randomised phase 3 trial. in The Lancet. Oncology / Lancet Oncol. 2014 Jun;15(7):713-21. doi: 10.1016/S1470-2045(14)70162-7. Epub 2014 May 13.

2014
AOU San Luigi di Orbassano
ASL Città di Torino

Gregorc V; Novello S; Lazzari C; Barni S; Aieta M; Mencoboni M; Grossi F; De Pas T; de Marinis F; Bearz A; Floriani I; Torri V; Bulotta A; Cattaneo A; Grigorieva J; Tsypin M; Roder J; Doglioni C; Levra MG; Petrelli F; Foti S; Viganò M; Bachi A; Roder H;

Randomized study of adjuvant chemotherapy for completely resected stage I, II, or IIIA non-small-cell Lung cancer. in Journal of the National Cancer Institute / J Natl Cancer Inst. 2003 Oct 1;95(19):1453-61. doi: 10.1093/jnci/djg059.

2003
AOU San Luigi di Orbassano

Scagliotti GV; Fossati R; Torri V; Crinò L; Giaccone G; Silvano G; Martelli M; Clerici M; Cognetti F; Tonato M;

HER-2/neu overexpression in patients with radically resected nonsmall cell lung carcinoma. Impact on long-term survival. in Cancer / Cancer. 2002 May 15;94(10):2669-74. doi: 10.1002/cncr.10531.

2002
AOU San Luigi di Orbassano

Selvaggi G; Scagliotti GV; Torri V; Novello S; Leonardo E; Cappia S; Mossetti C; Ardissone F; Lausi P; Borasio P;